Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Oct 21, 2024
Exosomes are tiny, powerful messengers that are revolutionizing the way we think about communication between cells. These nanosized vesicles carry crucial signals—proteins, lipids, and RNA—between cells, playing a pivotal role in everything from immune responses to tissue repair. What makes exosomes truly exciting ...
Read More...
Sep 02, 2024
CAR-T cells offer a lasting benefit through a single treatment, sparing patients with high-risk conditions from the toxicity associated with salvage chemotherapy and autologous transplants. These approvals have changed the standard of care for patients who are either resistant to initial treatment or experience ear...
Read More...
May 13, 2024
CAR-T therapy has been given the green light for treating blood cancers, but it hasn’t demonstrated sustained effectiveness against solid tumors thus far. The focus of ongoing CAR-T development leans heavily toward blood cancers rather than solid ones. On the other hand, bispecific antibodies have gained approval f...
Read More...
Feb 26, 2024
The category of T-cell therapy, which revolutionized the management of specific blood cancers, has now extended its impact to solid tumor treatment with the approval from the FDA of a groundbreaking immunotherapy pioneered by Iovance Biotherapeutics. Known as Amtagvi or lifileucel, this medication marks the debut o...
Read More...
Feb 07, 2024
As we step into the crisp corridors of 2024, the healthcare landscape unfolds a compelling saga of mergers, strategic funding, and transformative acquisitions. In this month-by-month analysis, we delve into the intricate tapestry of industry dynamics, exploring the impactful maneuvers that are shaping the healthcar...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper